bioMérieux S.A. (Euronext: BIM) announced today that it has concluded a settlement on several licence agreements with GeneOhm Sciences Canada, a subsidiary of Becton, Dickinson and Company, in the field of Methicillin-resistant Staphylococcus aureus (MRSA) detection. This settlement, whose financial terms are confidential, follows arbitration proceedings that bioMérieux initiated against GeneOhm Sciences Canada in April 2007. Stéphane Bancel, Chief Executive Officer of bioMérieux, stated: “This settlement confirms the relevance of the intellectual property rights held by bioMérieux in this field. bioMérieux intends to play a major role in protecting patients from healthcare-associated infections, among which Methicillin-resistant Staphylococcus aureus (MRSA) are of critical concern for hospital clinicians.”
Schweiz
bioMérieux launches the first automated detection test for Clostridium difficile A and B toxins
24 Juli, 2007
A new, rapid, and effective solution in the fight against hospital-acquired (nosocomial)infections. bioMérieux, a world leader in the field of in vitro diagnostics, (Euronext : BIM) has just launched VIDAS® C. difficile Toxin A&B, a test for the detection of a bacterium responsible for fatal nosocomial epidemics in Canada, the United States and, more recently, in Europe.
Sysmex and bioMérieux Form a Global Partnership
02 Juli, 2007
Kobe (Japan), Marcy l'Etoile (France) - July 2, 2007. Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) and bioMérieux (Euronext: BIM) have signed an agreement today by which bioMérieux will become Sysmex’s global partner for distributing its UF-1000i urinalysis system in microbiology laboratories.
Healthcare-Associated Infections : First World Forum on a critical public health issue
30 Mai, 2007
bioMérieux organizes the First World Forum on Healthcare-Associated Infections (HAI). This Forum will bring together around fifty international experts at the Mérieux Foundation Conference Center (Les Pensières, Veyrier-du-Lac, France) from June 4th to 5th 2007.
AdvanDx and bioMérieux Partner to Provide Rapid Results for Bloodstream Infections
22 Mai, 2007
In order to provide faster identification of bloodstream pathogens, bioMérieux (Euronext: BIM) has agreed with AdvanDx, Inc. to sign an exclusive distribution agreement for the United States for AdvanDx’s PNA FISH™ rapid diagnostic tests. These tests will be displayed at bioMérieux’s booth from the opening of the American Society of Microbiology (ASM) in Toronto on May 22.
bioMérieux Launches a Molecular Biology Test for the Detection of HPV, a Major Cause of Cervical Cancer
23 April, 2007
bioMérieux (Euronext: BIM) announces the launch of its NucliSENS EasyQ® HPV; this molecular diagnostic test enables the detection of human papillomavirus (HPV) in cervical cancer surveillance.